These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31074721)

  • 1. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients.
    Favalli EG; Conti F; Selmi C; Iannone F; Bucci R; D'Onofrio F; Carlino G; Santo L; Semeraro A; Zuccaro C; D'Angelo S; Atzeni F; Marino F; Monti S; Guidelli GM; Spinelli FR; Biggioggero M; Caporali R
    Clin Exp Rheumatol; 2020; 38(1):19-26. PubMed ID: 31074721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apremilast retention rate in clinical practice: observations from an Italian multi-center study.
    Ariani A; Parisi S; Del Medico P; Farina A; Visalli E; Molica Colella AB; Lumetti F; Caccavale R; Scolieri P; Andracco R; Girelli F; Bravi E; Colina M; Volpe A; Ianniello A; Franchina V; Platè I; Di Donato E; Amato G; Salvarani C; Lucchini G; De Lucia F; Molica Colella F; Santilli D; Ferrero G; Marchetta A; Arrigoni E; Mozzani F; Foti R; Sandri G; Bruzzese V; Paroli M; Fusaro E; Becciolini A
    Clin Rheumatol; 2022 Oct; 41(10):3219-3225. PubMed ID: 35796847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
    Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
    Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast.
    Venerito V; Natuzzi D; Bizzoca R; Lacarpia N; Cacciapaglia F; Lopalco G; Iannone F
    Clin Exp Immunol; 2020 Aug; 201(2):200-204. PubMed ID: 32383167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy.
    Capri S; Migliore A; Loconsole F; Barbieri M
    J Med Econ; 2020 Apr; 23(4):353-361. PubMed ID: 31856609
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
    Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.
    Coates LC; Nash P; Kvien TK; Gossec L; Mease PJ; Rasouliyan L; Pricop L; Jugl SM; Gandhi KK; Gaillez C; Smolen JS
    Semin Arthritis Rheum; 2020 Aug; 50(4):709-718. PubMed ID: 32521325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
    Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
    J Comp Eff Res; 2019 Jul; 8(9):699-709. PubMed ID: 31081676
    [No Abstract]   [Full Text] [Related]  

  • 13. The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids.
    Persson R; Hagberg KW; Qian Y; Vasilakis-Scaramozza C; Jick S
    Rheumatology (Oxford); 2021 Apr; 60(4):1926-1931. PubMed ID: 33159794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations.
    Mease PJ; Gladman DD; Ogdie A; Coates LC; Behrens F; Kavanaugh A; McInnes I; Queiro R; Guerette B; Brunori M; Teng L; Smolen JS
    Arthritis Care Res (Hoboken); 2020 Jun; 72(6):814-821. PubMed ID: 31909868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results.
    Ogdie A; Liu M; Glynn M; Emeanuru K; Harrold LR; Richter S; Guerette B; Mease PJ
    J Rheumatol; 2021 May; 48(5):693-697. PubMed ID: 33191289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
    Wu JJ; Pelletier C; Ung B; Tian M
    Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.
    Gorlier C; Orbai AM; Puyraimond-Zemmour D; Coates LC; Kiltz U; Leung YY; Palominos P; Cañete JD; Scrivo R; Balanescu A; Dernis E; Tälli S; Ruyssen-Witrand A; Soubrier M; Aydin SZ; Eder L; Gaydukova I; Lubrano E; Kalyoncu U; Richette P; Husni ME; de Wit M; Smolen JS; Gossec L
    Ann Rheum Dis; 2019 Feb; 78(2):201-208. PubMed ID: 30442648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
    Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
    Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice.
    Gratacós-Masmitja J; Beltrán Catalán E; Álvarez Vega JL; Urruticoechea-Arana A; Fito C; Maceiras F; Belzunegui Otano JM; Fernández Melón J; Chamizo Carmona E; Abad Hernández MÁ; Ros Vilamajó I; Castro Oreiro S; Pascual Alfonso E; Torre Alonso JC;
    Reumatol Clin (Engl Ed); 2024 Jan; 20(1):24-31. PubMed ID: 38233009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
    Wells AF; Edwards CJ; Kivitz AJ; Bird P; Guerette B; Delev N; Paris M; Teng L; Aelion JA
    Rheumatology (Oxford); 2022 Mar; 61(3):1035-1043. PubMed ID: 34100922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.